St. Jude Medical STJ, a global medical device company, today
announced organizational and leadership changes designed to improve growth.
The company will integrate its two operating divisions into one integrated
research and development organization, and will combine manufacturing and
supply chain operations worldwide.
Commenting on the announcement, St. Jude Medical Chairman, President and
Chief Executive Officer Daniel J. Starks said, "One reason 2013 was such a
successful year for us was that we streamlined our organization, improved
productivity, and reduced costs through organizational changes we announced
in August 2012. The changes we announced today will help us build on that
success to further leverage our scale, align on our highest priorities and
improve execution of our long-term growth program."
To help the company navigate through these significant operational changes,
Michael Rousseau, previously group president of St. Jude Medical, has been
promoted to chief operating officer. Rousseau will now oversee sales,
marketing, quality, technology development, operations and supply chain on a
global basis. Eric Fain, previously president, Implantable Electronic
Systems Division (IESD), has been promoted to group president of St. Jude
Medical and will now oversee all clinical, regulatory and research and
development activities across the company. Over the next several months,
Fain will lead the integration of IESD and the Cardiovascular and Ablation
Technologies Division (CATD) into one cohesive St. Jude Medical research and
development organization.
In addition, the company announced three new officers. Scott Thome is being
promoted to the newly created position of vice president, global operations
and supply chain; Lisa Andrade has been promoted to chief marketing officer;
and Jeff Dallager has been promoted to vice president, corporate controller.
St. Jude Medical also announced today that Frank Callaghan, previously
president, CATD, has decided to retire. Callaghan has been an integral part
of the St. Jude Medical leadership team since joining St. Jude Medical in
2005 as part of the Endocardial Solutions acquisition. He will remain an
advisor to the company through 2014.
"Frank has led the implementation of numerous technology programs within our
business and has been instrumental in driving our growth and reputation as
an industry leader in the cardiovascular market. St. Jude Medical sincerely
thanks him for his strong leadership and wishes him a wonderful transition
into retirement," said Starks.
About St. Jude Medical
St. Jude Medical is a global medical device manufacturer dedicated to
transforming the treatment of some of the world's most expensive, epidemic
diseases. The company does this by developing cost-effective medical
technologies that save and improve lives of patients around the world.
Headquartered in St. Paul, Minn., St. Jude Medical has four major clinical
focus areas that include cardiac rhythm management, atrial fibrillation,
cardiovascular and neuromodulation. For more information, please visit
sjm.com or follow us on Twitter @SJM_Media.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 that involve risks and
uncertainties. Such forward-looking statements include the expectations,
plans and prospects for the Company, including potential clinical successes,
anticipated regulatory approvals and future product launches, and projected
revenues, margins, earnings and market shares. The statements made by the
Company are based upon management's current expectations and are subject to
certain risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. These
risks and uncertainties include market conditions and other factors beyond
the Company's control and the risk factors and other cautionary statements
described in the Company's filings with the SEC, including those described
in the Risk Factors and Cautionary Statements sections of the Company's
Annual Report on Form 10-K for the fiscal year ended December 29, 2012 and
Quarterly Report on Form 10-Q for the fiscal quarter ended September 28,
2013. The Company does not intend to update these statements and undertakes
no duty to any person to provide any such update under any circumstance.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsManagement
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in